A cholesterol-lowering VLP vaccine that targets PCSK9

Vaccine

Volumn 33, Issue 43, 2015, Pages 5747-5755

  Crossey, Erin ^a   Amar, Marcelo J A ^b   Sampson, Maureen ^b   Peabody, Julianne ^a   Schiller, John T ^c   Chackerian, Bryce ^a   Remaley, Alan T ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

LDL Cholesterol; PCSK9; Vaccine; Virus like particles

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SECRETORY PROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; AUTOANTIBODY; CHOLESTEROL; DRUG CARRIER; IMMUNOGLOBULIN G; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG TARGETING; ENTEROBACTERIA PHAGE MS2; FEMALE; FOLLOW UP; HUMAN; MALE; MOUSE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RHESUS MONKEY; TRIACYLGLYCEROL BLOOD LEVEL; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIOPHAGE; BAGG ALBINO MOUSE; BLOOD; GENETICS; IMMUNOLOGY; MACACA; TREATMENT OUTCOME;

ANIMALS; AUTOANTIBODIES; BACTERIOPHAGES; CHOLESTEROL; DRUG CARRIERS; FEMALE; IMMUNOGLOBULIN G; MACACA; MALE; MICE, INBRED BALB C; PHOSPHOLIPIDS; PROPROTEIN CONVERTASES; TREATMENT OUTCOME; TRIGLYCERIDES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84944097535     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.044     Document Type: Article

References (47)

1. Cholesterol Treatment Trialists C., Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:380581-380590.
2. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119:676-683.
3. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553-564.
4. Qian Y.W., Schmidt R.J., Zhang Y., Chu S., Lin A., Wang H., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48:1488-1498.
5. Kwon H.J., Lagace T.A., McNutt M.C., Horton J.D., Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 2008, 105:1820-1825.
6. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
7. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
8. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
9. Ballantyne C.M., Neutel J., Cropp A., Duggan W., Wang E.Q., Plowchalk D., et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015, 115:1212-1221.
10. Robinson J.G., Farnier M., Krempf M., Bergeron J., Luc G., Averna M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1489-1499.
11. Sabatine M.S., Giugliano R.P., Wiviott S.D., Raal F.J., Blom D.J., Robinson J., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1500-1509.
12. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279:48865-48875.
13. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
14. Awan Z., Seidah N.G., MacFadyen J.G., Benjannet S., Chasman D.I., Ridker P.M., et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012, 58:183-189.
15. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003, 100:12027-12032.
16. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
17. Chackerian B., Durfee M.R., Schiller J.T. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 2008, 180:5816-5825.
18. Bachmann M.F., Whitehead P. Active immunotherapy for chronic diseases. Vaccine 2013, 31:1777-1784.
19. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821-827.
20. Tumban E., Peabody J., Peabody D.S., Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE 2011, 6:e23310.
21. Chackerian B., Rangel M., Hunter Z., Peabody D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006, 24:6321-6331.
22. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
23. Tumban E., Peabody J., Tyler M., Peabody D.S., Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS ONE 2012, 7:e49751.
24. Jawien J., Nastalek P., Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004, 55:503-517.
25. Zhang L., McCabe T., Condra J.H., Ni Y.G., Peterson L.B., Wang W., et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012, 8:310-327.
26. Galabova G., Brunner S., Winsauer G., Juno C., Wanko B., Mairhofer A., et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLOS ONE 2014, 9:e114469.
27. Chan J.C., Piper D.E., Cao Q., Liu D., King C., Wang W., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009, 106:9820-9825.
28. Liang H., Chaparro-Riggers J., Strop P., Geng T., Sutton J.E., Tsai D., et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012, 340:228-236.
29. Schiele F., Park J., Redemann N., Luippold G., Nar H. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J Mol Biol 2014, 426:843-852.
30. Abifadel M., Varret M., Rabes J-P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
31. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005, 102:2069-2074.
32. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101:7100-7105.
33. Shrank W., Lotvin A., Singh S., Brennan T. In the Debate about Cost and Efficacy, PCSK9 Inhibitors may be the Biggest Challenge Yet 2015, Health Affairs Blog, http://healthaffairs.org/blog/2015/02/17/in-the-debate-about-cost-and-efficacy-pcsk9-inhibitors-may-be-the-biggest-challenge-yet/2015.
34. Maningat P., Gordon B.R., Breslow J.L. How do we improve patient compliance and adherence to long-term statin therapy?. Curr Atheroscler Rep 2013, 15:291.
35. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
36. Cunningham D., Danley D.E., Geoghegan K.F., Griffor M.C., Hawkins J.L., Subashi T.A., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007, 14:413-419.
37. Piper D.E., Jackson S., Liu Q., Romanow W.G., Shetterly S., Thibault S.T., et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007, 15:545-552.
38. Allard D., Amsellem S., Abifadel M., Trillard M., Devillers M., Luc G., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26:497.
39. Cameron J., Holla Ø.L., Laerdahl J.K., Kulseth M.A., Ranheim T., Rognes T., et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008, 263:420-431.
40. Fattori E., Cappelletti M., Lo Surdo P., Calzetta A., Bendtsen C., Ni Y.G., et al. Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice. J Lipid Res 2012, 53:1654-1661.
41. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S1-S45.
42. Chackerian B., Lowy D.R., Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 1999, 96:2373-2378.
43. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
44. Fettelschoss A., Zabel F., Bachmann M.F. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother 2014, 10:847-851.
45. Bachmann M.F., Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004, 3:81-88.
46. Chackerian B., Briglio L., Albert P.S., Lowy D.R., Schiller J.T. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004, 78:4037-4047.
47. Van Rompay K.K., Hunter Z., Jayashankar K., Peabody J., Montefiori D., LaBranche C.C., et al. A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol 2014, 88:2011-2024.